Fakultni Nemocnice Plzen
- Address
- lock Available on a paid plan
Fakultni Nemocnice Plzen - Advanced Cancer and Blood Disorders Research Center
Fakultni Nemocnice Plzen is a comprehensive medical research institution with extensive expertise in hematologic malignancies and oncology. The center demonstrates particular strength in investigating novel therapeutic approaches for complex blood cancers and solid tumors, participating in multiple international Phase 2 and Phase 3 clinical trials across diverse therapeutic areas.
- Multiple Myeloma: Extensive research portfolio including newly diagnosed and relapsed/refractory cases, evaluating combination therapies with daratumumab, isatuximab, belantamab mafodotin, and CAR-T cell therapy with ciltacabtagene autoleucel
- Leukemia Disorders: Clinical trials in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and pediatric acute lymphoblastic leukemia, investigating targeted agents including venetoclax, acalabrutinib, and pirtobrutinib
- Lymphomas: Research in various B-cell lymphomas including mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphomas with novel immunotherapies
- Cardiovascular and Metabolic Diseases: Heart failure studies, pulmonary embolism intervention trials, and autoimmune conditions including plaque psoriasis and hidradenitis suppurativa
The center's research approach emphasizes personalized medicine and minimal residual disease monitoring, particularly in hematologic malignancies. With involvement in trials evaluating combination immunotherapies, bispecific antibodies, and targeted agents, Fakultni Nemocnice Plzen contributes significantly to advancing treatment paradigms for both common and rare diseases, including specialized studies in non-small cell lung cancer, renal cell carcinoma, and rare conditions such as hereditary angioedema and short bowel syndrome.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 180 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 171 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 30 by active trials.
- 1Novartis Pharma AG3active
lock +29 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International10trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fakultni Nemocnice Plzen
lock Showing 1 of 92 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21181) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of the central nervous system (CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 180 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 10 | Unknown | 2017-12-14 | 2025-09-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.